Current medical imaging · 2026
Preoperative Prediction of Fat-Suppressed T2-Weighted Imaging-based Breast Edema Scores for Lymphovascular Invasion in Patients with Breast Cancer.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Sun Ruihong, Wang Xi, Hu Yun, Huang Zengfa, Liu Hongyuan, Wang Xiang
Аннотация
INTRODUCTION: Lymphovascular invasion (LVI) is a critical prognostic factor in breast cancer, typically diagnosed via postoperative pathology. This study aimed to evaluate whether fat-suppressed T2-weighted imaging (FS T2WI)-based breast edema score (BES) combined with clinicopathological features could preoperatively predict LVI status.
MATERIALS AND METHODS: This retrospective study enrolled 574 breast cancer patients who underwent MRI and surgery from January 2021 to December 2023. Patients were classified as LVI-positive (n=174) or LVI-negative (n=400) based on postoperative pathology. Breast edema on FS T2WI was scored from 1 to 4 (BES 1, no edema; BES 2, peritumoral edema; BES 3, prepectoral edema; and BES 4, subcutaneous edema). Univariate and multivariate binary logistic regression analyses were performed to identify risk factors associated with LVI. A clinicopathological model and a combined BES–clinicopathological model were constructed, and diagnostic performance was evaluated using the area under the receiver operating characteristic curve (AUC) and the DeLong test.
RESULTS: Multivariate analysis revealed that BES and clinicopathological factors, including age, axillary lymph node metastasis, and tumor size, were independent predictors of LVI. Compared with BES 1, tumors with BES 2, BES 3, and BES 4 were associated with a 1.825-, 2.047-, and 4.341- fold increased LVI risk, respectively. The combined BES–clinicopathological model outperformed the clinicopathological model alone (AUC, 0.765 vs. 0.778; P<0.05).
DISCUSSION: Higher BES was independently associated with increased LVI risk. The predictive model integrating BES with clinicopathological variables outperformed single-parameter models, suggesting that BES may provide complementary imaging biomarkers for assessing tumor aggressiveness. Validation in larger, multicenter cohorts is warranted.
CONCLUSION: FS T2WI-based BES combined with clinicopathological features may improve preoperative prediction of LVI in breast cancer and support individualized treatment planning.
MATERIALS AND METHODS: This retrospective study enrolled 574 breast cancer patients who underwent MRI and surgery from January 2021 to December 2023. Patients were classified as LVI-positive (n=174) or LVI-negative (n=400) based on postoperative pathology. Breast edema on FS T2WI was scored from 1 to 4 (BES 1, no edema; BES 2, peritumoral edema; BES 3, prepectoral edema; and BES 4, subcutaneous edema). Univariate and multivariate binary logistic regression analyses were performed to identify risk factors associated with LVI. A clinicopathological model and a combined BES–clinicopathological model were constructed, and diagnostic performance was evaluated using the area under the receiver operating characteristic curve (AUC) and the DeLong test.
RESULTS: Multivariate analysis revealed that BES and clinicopathological factors, including age, axillary lymph node metastasis, and tumor size, were independent predictors of LVI. Compared with BES 1, tumors with BES 2, BES 3, and BES 4 were associated with a 1.825-, 2.047-, and 4.341- fold increased LVI risk, respectively. The combined BES–clinicopathological model outperformed the clinicopathological model alone (AUC, 0.765 vs. 0.778; P<0.05).
DISCUSSION: Higher BES was independently associated with increased LVI risk. The predictive model integrating BES with clinicopathological variables outperformed single-parameter models, suggesting that BES may provide complementary imaging biomarkers for assessing tumor aggressiveness. Validation in larger, multicenter cohorts is warranted.
CONCLUSION: FS T2WI-based BES combined with clinicopathological features may improve preoperative prediction of LVI in breast cancer and support individualized treatment planning.